Low dose naltrexone therapy in multiple sclerosis

Medical Hypotheses

Volumn 64, Issue 4, 2005, Pages 721-724

  Agrawal, Y P ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; NALOXONE; NALTREXONE;

APOPTOSIS; ARTICLE; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HEALTH SURVEY; HUMAN; LOW DRUG DOSE; MULTIPLE SCLEROSIS; MUSCLE STIFFNESS; NERVE CELL LESION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RECURRENCE RISK; SIDE EFFECT; TREATMENT OUTCOME; WAKEFULNESS;

EID: 13444252673     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.09.024     Document Type: Article

References (31)

1. L. Munari, R. Lovati, and A. Boiko Cochrane Database Syst Rev 2 2004
2. G.P.A. Rice, B. Incorvaia, and L. Munari Cochrane Database Syst Rev 2 2004
3. A. Chaudhuri, and P.O. Behan Shared scheme for assessing drugs for multiple sclerosis: why are eyes tightly shut to considering causes other than autoimmunity BMJ 326 2003 1213
4. M.H. Barnett, and J.W. Prineas Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion Ann Neurol 55 2004 458 468
5. P.O.C.A. Behan, and B.O. Roep Pathogenesis of multiple sclerosis revisited J R Coll Phys Edinb 32 2002 244 265
6. B.D. Trapp Pathogenesis of multiple sclerosis: the eyes only see what the mind is prepared to comprehend Ann Neurol 55 2004 455 457
7. C. Lucchinetti, W. Bruck, J. Parisi, B. Scheithauer, M. Rodriguez, and H. Lassmann Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination Ann Neurol 47 2000 707 717
8. M.P. Mycko, R. Papoian, U. Boschert, C.S. Raine, and K.W. Selmaj Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis Clin Neurol Neurosurg 106 2004 223 229
9. D.W. Ethell, and L.A. Buhler Fas ligand-mediated apoptosis in degenerative disorders of the brain J Clin Immunol 23 2003 363 370
10. F. Zipp Apoptosis in multiple sclerosis Cell Tissue Res 301 2000 163 171
11. Y. Gilgun-Sherki, E. Melamed, and D. Offen The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy J Neurol 251 2004 261 268
12. P. Werner, D. Pitt, and C.S. Raine Glutamate excitotoxicity - a mechanism for axonal damage and oligodendrocyte death in multiple Sclerosis J Neural Transm Supp 60 2000 375 385
13. D. Pitt, P. Werner, and C.S. Raine Glutamate excitotoxicity in a model of multiple sclerosis Nat Med 6 2000 67 70
14. C.C. Chao, S. Hu, T.W. Molitor, E.G. Shaskan, and P.K. Peterson Activated microglia mediate neuronal cell injury via a nitric oxide mechanism J Immunol 149 1992 2736 2741
15. B. Liu, H.M. Gao, J.Y. Wang, G.H. Jeohn, C.L. Cooper, and J.S. Hong Role of nitric oxide in inflammation-mediated neurodegeneration Ann N Y Acad Sci 962 2002 318 331
16. D. Gurwitz, and Y. Kloog Peroxynitrite generation might explain elevated glutamate and aspartate levels in multiple sclerosis cerebrospinal fluid Eur J Clin Invest 28 1998 760 761
17. K.E. Hill, L.V. Zollinger, H.E. Watt, N.G. Carlson, and J.W. Rose Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: distribution, cellular expression and association with myelin damage J Neuroimmunol 151 2004 171 179
18. H. Broholm, B. Andersen, and B. Wanscher Nitric oxide synthase expression and enzymatic activity in multiple sclerosis Acta Neurol Scand 109 2004 261 269
19. Nicholls M. MS sufferers campaign for drug aid. EDP24; May 21 2004
20. Calls for the radical treatment. The Irish times; May 18 2004
21. Weiss-Tisman H. Drug offers hope for MS patients. Brattleboro reformer; May 15 2004
22. Carswell S. MS experimental drug' could save state millions of euros'. The Sunday Business Post Online; Oct 5 2003
23. Puttick H. MS victim finds hope in heroin users drug. The Herald; April 12 2004
24. Undergrad J. Coping with an unprofitable cure. Columbia Spectator Online; May 1 2004
25. P.C. Singhal, M. Bhaskaran, and J. Patel Role of p38 mitogen-activated protein kinase phosphorylation and Fas-Fas ligand interaction in morphine-induced macrophage apoptosis J Immunol 168 2002 4025 4033
26. D.T. Lysle, and T. How Heroin modulates the expression of inducible nitric oxide synthase Immunopharmacology 46 2000 181 192
27. D.T. Lysle, and T. How Endogenous opioids regulate the expression of inducible nitric oxide synthase by splenocytes J Pharmacol Exp Ther 288 1999 502 508
28. J.F. Stover, K. Lowitzsch, and O.S. Kempski Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate-mediated excitotoxicity in different neurological diseases Neurosci Lett 238 1997 25 28
29. J.W. Rose, K.E. Hill, H.E. Watt, and N.G. Carlson Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion J Neuroimmunol 149 2004 40 49
30. D. Trotti, D. Rossi, and O. Gjesdal Peroxynitrite inhibits glutamate transporter subtypes J Biol Chem 271 1996 5976 5979
31. T. Smith, A. Groom, B. Zhu, and L. Turski Autoimmune encephalomyelitis ameliorated by AMPA antagonists Nat Med 6 2000 62 66